Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
modified-release thyrotropin alfa
- Development stage
- Phase 2
- Lead developer
- Sanofi
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
Modified-release thyrotropin alfa (MRrhTSH) is a long-acting formulation of recombinant human thyroid-stimulating hormone (rhTSH). Developed by Genzyme (a Sanofi company), it was designed to provide a sustained elevation of serum TSH levels compared to the immediate-release formulation (thyrotropin alfa, marketed as Thyrogen). The primary therapeutic goal of the modified-release version was to enhance the effectiveness of radioactive iodine (131-I) therapy in patients with non-toxic multinodular goiter (MNG). By maintaining elevated TSH levels over a longer period, the drug stimulates more uniform and increased iodine uptake by thyroid tissue, which can lead to a more significant reduction in goiter volume and improvement in compressive symptoms while potentially allowing for lower doses of radioiodine. Although it showed promise in Phase 2 clinical trials, development for multinodular goiter was eventually discontinued by Sanofi.
- Brand names
- Thyrogen
- Other names
- modified-release recombinant human thyroid stimulating hormonesustained-release thyrotropin alfa
02
Targets
TSHR (Thyroid-stimulating hormone receptor)
Beyond the preview
Go deeper on modified-release thyrotropin alfa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on modified-release thyrotropin alfa.